SPOTLIGHT: Novartis touts positive Diovan data

Novartis is reporting positive data from a Japanese study of Diovan in combination with conventional therapy as a treatment for high blood pressure. New data on the combination therapy revealed a 39 percent reduction in cardiovascular events and a 40 percent reduction of strokes among the 3,000 volunteers in the trial. Report